Holen Sie sich die Stockscreener-App
151.44
1.83%
-2.83
Handel nachbörslich:
151.43
-0.010
-0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$154.27
Offen:
$153.6
24-Stunden-Volumen:
2.20M
Relative Volume:
1.34
Marktkapitalisierung:
$22.20B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.53B
KGV:
14.49
EPS:
10.453
Netto-Cashflow:
$1.85B
1W Leistung:
+0.67%
1M Leistung:
-5.28%
6M Leistung:
+22.59%
1J Leistung:
-12.86%
1-Tages-Spanne:
$149.63
$155.33
1-Wochen-Bereich:
$138.00
$155.33
52-Wochen-Spanne:
$110.03
$179.20
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
151.44 | 22.63B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
896.53 | 772.28B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.26 | 455.04B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
211.96 | 385.18B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
123.86 | 237.53B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
82.49 | 214.76B | 63.99B | 19.05B | 14.72B | 7.5596 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Behavioral Patterns of BIIB and Institutional Flows - news.stocktradersdaily.com
BIIB: Bernstein Raises Price Target for Biogen to $157 with Mark - GuruFocus
Biogen to present felzartamab data at Kidney Week 2025 - Investing.com
Biogen (BIIB) Reveals New Data on Felzartamab at Kidney Week 202 - GuruFocus
Why Biogen Inc. (IDP) stock stays on top picksJuly 2025 Patterns & AI Powered Market Entry Strategies - newser.com
Biogen Inc. to Present Groundbreaking Longitudinal Gene Expression Data on Felzartamab at Kidney Week 2025 - Quiver Quantitative
Biogen Inc. $BIIB Shares Bought by State of Michigan Retirement System - MarketBeat
Plato Investment Management Ltd Raises Stock Holdings in Biogen Inc. $BIIB - MarketBeat
FY2025 EPS Estimates for Biogen Decreased by Leerink Partnrs - MarketBeat
Should you wait for a breakout in Biogen Inc.2025 Key Lessons & Smart Money Movement Tracker - newser.com
How to escape a deep drawdown in Biogen Inc.Portfolio Update Summary & High Conviction Buy Zone Alerts - newser.com
Amgen Earnings: What To Look For From AMGN - FinancialContent
Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Guggenheim Increases Biogen (NASDAQ:BIIB) Price Target to $185.00 - MarketBeat
Biogen (NASDAQ:BIIB) Given New $150.00 Price Target at BMO Capital Markets - MarketBeat
Biogen (NASDAQ:BIIB) Price Target Raised to $143.00 - MarketBeat
Biotech Investments Market Seeking Excellent Growth | Biogen (US), Moderna, Johnson & Johnson - openPR.com
How a Strong Q3 and Increased R&D Spending at Biogen (BIIB) Has Changed Its Investment Story - simplywall.st
Biogen shares drop as full-year guidance cut outweighs strong Q3 results - MSN
Savvy Advisors Inc. Buys New Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Stock Holdings Increased by Wealthfront Advisers LLC - MarketBeat
Biogen (NASDAQ:BIIB) Stock Rating Lowered by Wall Street Zen - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Q3 2025 Earnings Call Transcript - Insider Monkey
Biogen’s Earnings Call Highlights Robust Growth and Positive Outlook - The Globe and Mail
Key metrics from Biogen Inc.’s quarterly dataWeekly Profit Recap & Precise Swing Trade Entry Alerts - newser.com
Institutional scanner results for Biogen Inc.Options Play & Free Community Supported Trade Ideas - newser.com
Royal Bank Of Canada Lowers Biogen (NASDAQ:BIIB) Price Target to $210.00 - MarketBeat
Biogen (NASDAQ:BIIB) Price Target Cut to $250.00 by Analysts at Robert W. Baird - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Option Care Health (OPCH) and Amneal Pharmaceuticals (AMRX) - The Globe and Mail
Biogen outlines 67% launch product growth and signals expanded pipeline momentum amid strong Q3 results - MSN
Sector ETF performance correlation with Biogen Inc.Trade Analysis Report & Consistent Profit Focused Trading Strategies - newser.com
Fjarde AP Fonden Fourth Swedish National Pension Fund Has $3.44 Million Stake in Biogen Inc. $BIIB - MarketBeat
Analyzing Biogen Inc. with multi timeframe chartsTrade Volume Summary & Long-Term Growth Plans - newser.com
Is Biogen Inc. stock a top momentum playWeekly Trend Recap & Reliable Intraday Trade Plans - newser.com
Biogen Inc. Reports Strong Q3 2025 Results - The Globe and Mail
Biogen (NASDAQ:BIIB) Issues Earnings Results - MarketBeat
BMO Capital Adjusts Biogen Price Target to $150 From $128 - MarketScreener
Biogen (BIIB) Rating Maintained as RBC Capital Lowers Price Targ - GuruFocus
BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands - Yahoo Finance
Wedbush Raises Price Target on Biogen to $143 From $135, Keeps Neutral Rating - MarketScreener
Wells Fargo Adjusts Price Target on Biogen to $155 From $140 - MarketScreener
Baird Adjusts Price Target on Biogen to $250 From $255 - MarketScreener
Biogen (NASDAQ:BIIB) Issues FY 2025 Earnings Guidance - MarketBeat
Biogen (BIIB): One-Time $471M Loss Raises Fresh Doubts Over Rebounding Profit Narrative - Yahoo Finance
RBC Cuts Price Target on Biogen to $210 From $217, Keeps Outperform Rating - MarketScreener
Volatility clustering patterns for Biogen Inc.Market Activity Summary & Fast Gain Swing Alerts - newser.com
Emerald Advisers LLC Makes New Investment in Biogen Inc. $BIIB - MarketBeat
Biogen Lowers Outlook Even As Profits And Sales Top Estimates - Finimize
How Biogen Inc. (IDP) stock behaves in tightening cyclesStock Surge & Low Risk High Reward Trade Ideas - newser.com
When is the best time to exit Biogen Inc.July 2025 Volume & Free Community Supported Trade Ideas - newser.com
Biogen stock price target raised to $185 from $165 at Guggenheim - Investing.com
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.05%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):